Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

Asian Insight Provider - Actionable ideas

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

Despite the lockdown and ceaseless increase in the infection cases in Indonesia, the mobility rate in the workplace has improved by 50% that helped to narrow Q3 2020 loss apart from the cost savings initiative. 
Vaccine discovery has helped Bluebird's share price ascension but the real push will come from the vaccination in Indonesia that will lead to a looser government policy lockdown and it is bound to create a more permanent feeling that it is business as usual (pre-COVID) therefore may even lead to a re-opening of the borders. 
<div class="content-highlight">
At 9.8 EV/EBITDA and 0.73 PBR, <a href="https://www.smartkarma.com/entities/blue-bird-tbk-pt" target="_blank" data-smartkarma-citation="entities:19482:1" rel="noopener">Blue Bird (BIRD IJ)</a> is currently trading at 42% and 44% discount in EV/EBITDA and PBR compared to its peers despite a 57% rally. We should expect to see further multiple expansion in Blue Bird as mass vaccination is taking place and people have more confidence in the economic recovery in Indonesia. 
</div>
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/182/498/original/image_2762037721610626999059.png?1610626999" class="editor-image img-responsive" data-smartkarma-image-id="182498"></figure>
<div class="content-remarks">
source: Capital IQ
</div>

Despite the lockdown and ceaseless increase in the infection cases in Indonesia, the mobility rate in the workplace has improved by 50% that helped to narrow Q3 2020 loss apart from the cost savings initiative. 
Vaccine discovery has helped Bluebird's share price ascension but the real push will come from the vaccination in Indonesia that will lead to a looser government policy lockdown and it is bound to create a more permanent feeling that it is business as usual (pre-COVID) therefore may even lead to a re-opening of the borders. 

At 9.8 EV/EBITDA and 0.73 PBR, Blue Bird (BIRD IJ) is currently trading at 42% and 44% discount in EV/EBITDA and PBR compared to its peers despite a 57% rally. We should expect to see further multiple expansion in Blue Bird as mass vaccination is taking place and people have more confidence in the economic recovery in Indonesia. 



source: Capital IQ


HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

First of all, Merry Christmas and Happy New Year!
1. Industry viewpoints:
<ul>
<li>While we are still waiting for the official results of the volume-based purchase (VBP) negotiations in 2020, let’s take a further look at the competitive landscape of PD-1/L1 in China.</li>
<li>The regenerative medical implant devices would be a development trend of medical implant devices in the future.</li>
<li>Affected by the centralized procurement policy in China, the growth rate of high-value medical consumables market is expected to slow year by year.</li>
</ul>
2. Company news:
News about the progress of new drugs from <a href="https://www.smartkarma.com/entities/alphamab-oncology" target="_blank" data-smartkarma-citation="entities:28213:1" rel="noopener">Alphamab Co Ltd (9966 HK)</a>, <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, <a href="https://www.smartkarma.com/entities/ascletis-pharma-inc" target="_blank" data-smartkarma-citation="entities:27265:1" rel="noopener">Ascletis Pharma Inc (1672 HK)</a> and <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a>.
3. Market review:
Last week, stock price for healthcare sector in A share increased 1.1%, while CSI 300 increased 0.84% over the same period of time.
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

First of all, Merry Christmas and Happy New Year!
1. Industry viewpoints:

While we are still waiting for the official results of the volume-based purchase (VBP) negotiations in 2020, let’s take a further look at the competitive landscape of PD-1/L1 in China.
The regenerative medical implant devices would be a development trend of medical implant devices in the future.
Affected by the centralized procurement policy in China, the growth rate of high-value medical consumables market is expected to slow year by year.

2. Company news:
News about the progress of new drugs from Alphamab Co Ltd (9966 HK), Innovent Biologics Inc (1801 HK), Ascletis Pharma Inc (1672 HK) and Jiangsu Hengrui Medicine (600276 CH).
3. Market review:
Last week, stock price for healthcare sector in A share increased 1.1%, while CSI 300 increased 0.84% over the same period of time.
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

Eddingpharm is a China-based pharmaceutical company that has filed an Application Proof to list on the HKEX. The product line consist of older drugs with varying degrees of exposure to the government's VBP/GQCE program. The development pipeline has two intriguing candidates that should come to market in 2022. We think the overarching issue for the shares will be whether enthusiasm for the pipeline can offset the VBP-related overhang. 
This Insight addresses the company's products and market opportunity, and leave other topics to a future Insight. Our Bullish tag is a placeholder until we get closer to an offering.

Eddingpharm is a China-based pharmaceutical company that has filed an Application Proof to list on the HKEX. The product line consist of older drugs with varying degrees of exposure to the government's VBP/GQCE program. The development pipeline has two intriguing candidates that should come to market in 2022. We think the overarching issue for the shares will be whether enthusiasm for the pipeline can offset the VBP-related overhang. 
This Insight addresses the company's products and market opportunity, and leave other topics to a future Insight. Our Bullish tag is a placeholder until we get closer to an offering.

<div>
Antengene Corporation, which has filed for an HKEX listing, is a pre-revenue pharmaceutical company focused a combinatory (drug combinations) to treat cancer. The company's pipeline primarily features late-stage, in-licensed products (one approved in the US) supplemented by several internally-developed, pre-clinical compounds. The management team comes from <a href="https://www.smartkarma.com/entities/celgene-corp" target="_blank" data-smartkarma-citation="entities:7410:1" rel="noopener">Celgene Corp (CELG US)</a> and other MNCs and has experience developing oncology products. The venture investors are credible; and the patent estate has a long life.
</div>
<div>
This Insight provides an overview of the business, including some initial thoughts on valuation (US$1-1.5 billion), and a list of questions for management. We will provide an update in a future Insight.
</div>


Antengene Corporation, which has filed for an HKEX listing, is a pre-revenue pharmaceutical company focused a combinatory (drug combinations) to treat cancer. The company's pipeline primarily features late-stage, in-licensed products (one approved in the US) supplemented by several internally-developed, pre-clinical compounds. The management team comes from Celgene Corp (CELG US) and other MNCs and has experience developing oncology products. The venture investors are credible; and the patent estate has a long life.


This Insight provides an overview of the business, including some initial thoughts on valuation (US$1-1.5 billion), and a list of questions for management. We will provide an update in a future Insight.


1. Industry viewpoints: <ul>
<li>China’s new intensive procurement policy has finally been applied to high-value medical consumables. Thus, related medical device companies are facing new challenges.</li>
<li>
With the increase of patients' affordability and doctors' cognition and acceptance of minimally invasive surgery, it is expected that MISIA market will have greater growth potential in the near future. 
</li>
<li>In recent years, China cancer drug market has grown rapidly. With large growth potential in this market and more favorable policy, more innovative cancer drugs will be approved in China</li>
</ul>2. Company newsNews of Jiangsu Hengrui Medicine, Dingdang Kuaiyao and AstraZeneca China on the cooperation of new drugs and the progress of new funding.3. Market reviewLast week, stock price for healthcare sector in A share decreased 6.24%, while CSI 300 decreased 1.53% over the same period of time.

1. Industry viewpoints: 
China’s new intensive procurement policy has finally been applied to high-value medical consumables. Thus, related medical device companies are facing new challenges.

With the increase of patients' affordability and doctors' cognition and acceptance of minimally invasive surgery, it is expected that MISIA market will have greater growth potential in the near future. 

In recent years, China cancer drug market has grown rapidly. With large growth potential in this market and more favorable policy, more innovative cancer drugs will be approved in China
2. Company newsNews of Jiangsu Hengrui Medicine, Dingdang Kuaiyao and AstraZeneca China on the cooperation of new drugs and the progress of new funding.3. Market reviewLast week, stock price for healthcare sector in A share decreased 6.24%, while CSI 300 decreased 1.53% over the same period of time.

United Kingdom

AstraZeneca PLC operates as a holding company. The Company, through its subsidiaries, researches, manufactures, and sells pharmaceutical and medical products. AstraZeneca focuses its operations on eight therapeutic areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AstraZeneca PLC (AZN LN)

BlueBird (BIRD): Flying Higher

At 9.8 EV/EBITDA and 0.73 PBR, Blue Bird (BIRD IJ) is currently trading at 42% and 44% discount in EV/EBITDA and PBR compared to its peers despite...

Henry Soediarko

China Healthcare Weekly (Dec.25)

This article analyzed healthcare industry viewpoints such as competitive landscape of PD-1/L1 in China, news of Alphamab, Hengrui, Innovent and...

Xinyao (Criss) Wang

Eddingpharm: First Impressions

Eddingpharm plans to list on the HKEX. This Insight analyzes the company's products and pipeline. The main question is whether enthusiasm for the...

Kemp Dolliver, CFA

Antengene: Gunning To Move Up in Line

This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...

Kemp Dolliver, CFA

China Healthcare Weekly (Oct.23)

This article summarized important new China healthcare policy released last week, major industry viewpoints, company news and market review for...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)